Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

证券日报网讯博晖创新（300318）11月12日在互动平台回答投资者提问时表示，公司股东人数可关注公 司披露的定期报告。 ...

资金流向方面，今日该股主力资金净流入8193.13万元，其中，特大单净流入8723.76万元，大单资金净 流出530.63万元。近5日主力资金净流入7863.67万元。（数据宝） 博晖创新今日涨停，全天换手率8.16%，成交额4.58亿元，振幅19.60%。龙虎榜数据显示，机构净卖出 1542.67万元，深股通净卖出29.50万元，营业部席位合计净买入3805.26万元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净卖出1542.67万元，深 股通净卖出29.50万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交1.37亿元，其中，买入成交额为7942.16 万元，卖出成交额为5709.07万元，合计净买入2233.09万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即卖一，合计净卖出1542.67万元，深股 通为第五大卖出营业部，买入金额为803.71万元，卖出金额为833.21万元，合计净卖出29.50万元。 （原标题：博晖创新龙虎榜数据（11月12日）） 博晖创新11月12日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） ...

Core Viewpoint - The biopharmaceutical sector experienced a slight increase of 0.44% on November 12, with significant gains from specific stocks, while the overall market indices showed a decline [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4000.14, down 0.07% - The Shenzhen Component Index closed at 13240.62, down 0.36% [1] Group 2: Top Gainers in Biopharmaceutical Sector - BGI Innovation (300318) led the gains with a closing price of 7.20, up 20.00% with a trading volume of 651,300 shares and a transaction value of 458 million yuan - Sanyuan Gene (920344) followed with a closing price of 33.15, up 12.45% and a trading volume of 85,300 shares [1] - Other notable gainers include: - Sangfor Biopharma (688336) at 68.50, up 6.60% - Sai Sheng Pharmaceutical (300485) at 12.88, up 4.63% [1] Group 3: Market Capital Flow - The biopharmaceutical sector saw a net inflow of 325 million yuan from institutional investors, while retail investors experienced a net outflow of 317 million yuan [2] - The top stocks by net inflow from institutional investors included: - Sangfor Biopharma (688336) with a net inflow of 136 million yuan - He Yuan Biopharma (688765) with a net inflow of 108 million yuan [3]

Core Insights - The monkeypox concept sector saw a rise of 1.57%, ranking third among concept sectors, with 57 stocks increasing in value, including significant gains from companies like Bo Hui Innovation, which hit a 20% limit up, and others like He Fu China and Zhong Sheng Pharmaceutical reaching their daily limit up as well [1][2] Group 1: Market Performance - The monkeypox concept sector had a net inflow of 5.92 billion yuan, with 35 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top net inflow was from Zhong Sheng Pharmaceutical, which saw a net inflow of 4.36 billion yuan, followed by Fu Xiang Pharmaceutical and Bo Hui Innovation with net inflows of 1.28 billion yuan and 819.31 million yuan respectively [2][3] Group 2: Stock Performance - The stocks with the highest net inflow ratios included Bo Hui Innovation at 17.88%, Zhong Sheng Pharmaceutical at 14.67%, and Dong Fang Biological at 13.11% [3] - Notable stock performances included Bo Hui Innovation with a 20% increase, Zhong Sheng Pharmaceutical with a 10.02% increase, and He Fu China with a 10.02% increase as well [1][7]

Core Viewpoint - The Shanghai Composite Index decreased by 0.21% today, with significant declines in the electric equipment sector, which saw the largest drop of 2.31% [2] Industry Performance Summary - The oil and petrochemical sector led the gains with an increase of 1.27%, followed by the banking sector at 1.10% and the comprehensive sector at 1.01% [2] - The electric equipment sector experienced the largest decline at 2.31%, followed by the defense and military industry at 1.70% and the computer sector at 1.28% [2] - A total of 1513 stocks rose, with 65 hitting the daily limit up, while 3819 stocks fell, including 10 hitting the daily limit down [2] Trading Volume and Value - The total trading volume reached 1,081 million shares, with a total transaction value of 15,923.01 billion yuan, reflecting a decrease of 1.61% compared to the previous trading day [2]

Market Overview - The Shanghai Composite Index increased by 0.27% as of 10:28 AM, with a trading volume of 61.67 billion shares and a transaction value of 893.47 billion yuan, a decrease of 6.50% compared to the previous trading day [1] Industry Performance - The top-performing industries included: - Oil and Petrochemicals: Increased by 1.77% with a transaction value of 8.62 billion yuan, led by Sinopec Oilfield Service, which rose by 10.21% [1] - Banking: Increased by 1.52% with a transaction value of 15.41 billion yuan, led by Agricultural Bank of China, which rose by 2.89% [1] - Home Appliances: Increased by 1.01% with a transaction value of 14.36 billion yuan, led by Beiyikang, which rose by 10.78% [1] - The worst-performing industries included: - Communication: Decreased by 1.33% with a transaction value of 34.89 billion yuan, led by Yongding Co., which fell by 5.45% [2] - Electric Power Equipment: Decreased by 1.25% with a transaction value of 148.46 billion yuan, led by Canadian Solar, which fell by 13.92% [2] - National Defense and Military Industry: Decreased by 0.92% with a transaction value of 16.72 billion yuan, led by Triangle Defense, which fell by 7.34% [2] Stock Performance - A total of 1,864 stocks rose, with 49 hitting the daily limit, while 3,394 stocks fell, with 2 hitting the lower limit [1]

Group 1 - The flu concept is experiencing renewed activity, leading to significant stock movements in related companies [1] - Te Yi Pharmaceutical has achieved two consecutive trading limits, indicating strong market interest [1] - Bo Hui Innovation has reached a 20% daily limit increase, reflecting positive investor sentiment [1] Group 2 - Panlong Pharmaceutical has also hit the daily limit, showcasing its strong performance in the market [1] - Other companies such as Zhongsheng Pharmaceutical, Ha Sanlian, and Jinhua Co. have seen their stocks rise in response to the flu concept's resurgence [1]

智通财经APP讯，博晖创新(300318.SZ)发布公告，近日，公司控股孙公司博晖生物制药股份有限公司 (以下简称"廊坊博晖")与北京百晖生物科技有限公司(以下简称"百晖生物")联合申报的冻干b型流感嗜血 杆菌结合疫苗，获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意开展临床试验。 据悉，廊坊博晖与百晖生物联合申报的冻干b型流感嗜血杆菌结合疫苗，通过纯化的Hib荚膜多糖抗原与 破伤风类毒素结合生成的多糖蛋白结合物刺激机体产生免疫反应，用于预防由b型流感嗜血杆菌引起的 侵袭性感染(脑膜炎、肺炎、败血症、蜂窝组织炎、关节炎、会厌炎等)。目前国内已上市的冻干Hib结 合疫苗厂家包括北京民海生物科技有限公司。 ...

Core Viewpoint - The company BoHui Innovation (300318.SZ) announced that its subsidiary BoHui Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of a lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine [1] Group 1 - The lyophilized Hib conjugate vaccine is developed in collaboration with Beijing Baihui Biotechnology Co., Ltd. [1] - The vaccine aims to stimulate immune response through a purified Hib capsular polysaccharide antigen combined with tetanus toxoid, targeting invasive infections caused by Hib, such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [1]